March 5, 2019
Amgen Astellas BioPharma on March 4 rolled out Evenity (romosozumab) in Japan for the treatment of osteoporosis in patients with a high risk of fractures, marking the world’s first launch of the humanized anti-sclerostin monoclonal antibody. Evenity carries an NHI...read more